Dicot Pharma
0.38 SEK
-0.11 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Dicot Pharma
EV/S
Median 2022-2023
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 1.08 | 0.49 | 0.34 | 0.16 | 0.23 | 0.24 | 0.31 |
| Shares | 42.1 | 61.2 | 106.7 | 281.4 | 1,111.6 | 1,778.8 | 2,009.3 |
| Market cap | 45.6 | 29.9 | 36.1 | 46.1 | 260.0 | 431.4 | 616.9 |
| Enterprise value | 33.4 | 9.5 | 5.8 | 36.7 | 212.6 | - | - |
| EV/S | - | - | - | 305.7 | 924.5 | - | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | - | - |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 3.57 | 1.52 | 1.27 | 8.59 | 5.86 | 3.86 | 8.40 |
| P/S | - | - | - | 383.9 | 1,130.4 | - | - |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 91.0 % | 91.0 % | 89.2 % | 43.3 % | 82.9 % | 90.4 % | 85.8 % |
| Gearing ratio | - | - | - | - | - | - | - |